Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.77, read 2026-11-02
Ethical does not pass the values gate
Price15.44 USD
Fair value8.75
Ethical score70.0/100
Value readOvervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-02Read Markup11.97+29.0% to today ✓Distribution gives way to Markup first Markup read since August
2026-09-11Read Distribution12.20+26.6% to today Markup gives way to Distribution after a 71% rise in 10 weeks
2026-07-02Read Markup7.14+116.2% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Rapid7 Inc holds its Markup at $15.44. Consolidating, no directional conviction, held for 21 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 21 days
Price at the screen
$15.44
Valuation
34.20 trailing · 7.70 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.01
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
56.09%
Below 33%
Interest-bearing debt is 56.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
13.21%
Below 33%
Cash held in interest-bearing accounts and securities is 13.2% of assets, under the one-third limit.
Pass
Receivables
23.96%
Below 49%
Money owed to the company is 24.0% of assets, under the 49% limit.
Pass
Revenue purity
2.68%
Below 5%
Only 2.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Rapid7's business is in a permissible area, but its interest-bearing debt is about 56% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RPD's ethical verdict changes
Today RPD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 5 Nov 2026: it trades above our $8.75 fair value estimate, none competitive moat.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 76.5% above the base estimate.
Where our models see it going: fair-value estimate $8.75, with a range of $8.75 to $30.88, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 7.7x forward earnings, the price already runs ahead of the business. It trades 76% above our $8.75 fair value, so you would be buying at a premium, not a discount. The none moat is real, but quality alone does not make an expensive price cheap.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RPD trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$14.84-10.4%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 70%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (22 analysts) rates it hold, with a mean price target of $7. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$16.56+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 70%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (22 analysts) rates it hold, with a mean price target of $7. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$16.56+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 70%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (22 analysts) rates it hold, with a mean price target of $7. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$16.56+11.1%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 70%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (22 analysts) rates it hold, with a mean price target of $7. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$14.91+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 70%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (22 analysts) rates it hold, with a mean price target of $7. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$14.91+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 70%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (22 analysts) rates it hold, with a mean price target of $7. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$14.91+20.4%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 20.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 70%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (22 analysts) rates it hold, with a mean price target of $7. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$12.38+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are down 70%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (22 analysts) rates it hold, with a mean price target of $7. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markup$12.38-9.9%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 70%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (22 analysts) rates it hold, with a mean price target of $7.
2026-10-14Markup$13.74+14.8%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 70%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (22 analysts) rates it hold, with a mean price target of $7.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.